Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 148

1.

Combined TLR2/4-activated dendritic/tumor cell fusions induce augmented cytotoxic T lymphocytes.

Koido S, Homma S, Okamoto M, Namiki Y, Takakura K, Takahara A, Odahara S, Tsukinaga S, Yukawa T, Mitobe J, Matsudaira H, Nagatsuma K, Uchiyama K, Kajihara M, Arihiro S, Imazu H, Arakawa H, Kan S, Komita H, Ito M, Ohkusa T, Gong J, Tajiri H.

PLoS One. 2013;8(3):e59280. doi: 10.1371/journal.pone.0059280. Epub 2013 Mar 15.

2.

Augmentation of antitumor immunity by fusions of ethanol-treated tumor cells and dendritic cells stimulated via dual TLRs through TGF-β1 blockade and IL-12p70 production.

Koido S, Homma S, Okamoto M, Namiki Y, Takakura K, Takahara A, Odahara S, Tsukinaga S, Yukawa T, Mitobe J, Matsudaira H, Nagatsuma K, Kajihara M, Uchiyama K, Arihiro S, Imazu H, Arakawa H, Kan S, Hayashi K, Komita H, Kamata Y, Ito M, Hara E, Ohkusa T, Gong J, Tajiri H.

PLoS One. 2013 May 24;8(5):e63498. doi: 10.1371/journal.pone.0063498. Print 2013.

3.

Streptococcal preparation OK-432 promotes fusion efficiency and enhances induction of antigen-specific CTL by fusions of dendritic cells and colorectal cancer cells.

Koido S, Hara E, Homma S, Torii A, Mitsunaga M, Yanagisawa S, Toyama Y, Kawahara H, Watanabe M, Yoshida S, Kobayashi S, Yanaga K, Fujise K, Tajiri H.

J Immunol. 2007 Jan 1;178(1):613-22.

4.

Synergistic induction of antigen-specific CTL by fusions of TLR-stimulated dendritic cells and heat-stressed tumor cells.

Koido S, Hara E, Homma S, Mitsunaga M, Takahara A, Nagasaki E, Kawahara H, Watanabe M, Toyama Y, Yanagisawa S, Kobayashi S, Yanaga K, Fujise K, Gong J, Tajiri H.

J Immunol. 2007 Oct 1;179(7):4874-83.

5.
6.

Induction of impaired antitumor immunity by fusion of MHC class II-deficient dendritic cells with tumor cells.

Tanaka Y, Koido S, Ohana M, Liu C, Gong J.

J Immunol. 2005 Feb 1;174(3):1274-80.

7.

In vitro generation of cytotoxic and regulatory T cells by fusions of human dendritic cells and hepatocellular carcinoma cells.

Koido S, Homma S, Hara E, Mitsunaga M, Namiki Y, Takahara A, Nagasaki E, Komita H, Sagawa Y, Ohkusa T, Fujise K, Gong J, Tajiri H.

J Transl Med. 2008 Sep 15;6:51. doi: 10.1186/1479-5876-6-51.

8.

Uncarinic acid C plus IFN-γ generates monocyte-derived dendritic cells and induces a potent Th1 polarization with capacity to migrate.

Bae WK, Umeyama A, Chung IJ, Lee JJ, Takei M.

Cell Immunol. 2010;266(1):104-10. doi: 10.1016/j.cellimm.2010.09.004. Epub 2010 Sep 18.

PMID:
20933226
9.
10.

Protein-bound polysaccharide activates dendritic cells and enhances OVA-specific T cell response as vaccine adjuvant.

Engel AL, Sun GC, Gad E, Rastetter LR, Strobe K, Yang Y, Dang Y, Disis ML, Lu H.

Immunobiology. 2013 Dec;218(12):1468-76. doi: 10.1016/j.imbio.2013.05.001. Epub 2013 May 13.

11.

Gene silencing of TGF-β1 enhances antitumor immunity induced with a dendritic cell vaccine by reducing tumor-associated regulatory T cells.

Conroy H, Galvin KC, Higgins SC, Mills KH.

Cancer Immunol Immunother. 2012 Mar;61(3):425-31. doi: 10.1007/s00262-011-1188-y. Epub 2011 Dec 23.

PMID:
22193988
12.
13.

Enhancement of the antigen-specific cytotoxic T lymphocyte-inducing ability in the PMDC11 leukemic plasmacytoid dendritic cell line via lentiviral vector-mediated transduction of the caTLR4 gene.

Iwabuchi M, Narita M, Uchiyama T, Iwaya S, Oiwa E, Nishizawa Y, Hashimoto S, Bonehill A, Kasahara N, Takizawa J, Takahashi M.

Mol Med Rep. 2015 Aug;12(2):2443-50. doi: 10.3892/mmr.2015.3685. Epub 2015 Apr 24.

14.

Induction of antigen-specific CD4- and CD8-mediated T-cell responses by fusions of autologous dendritic cells and metastatic colorectal cancer cells.

Koido S, Hara E, Torii A, Homma S, Toyama Y, Kawahara H, Ogawa M, Watanabe M, Yanaga K, Fujise K, Gong J, Toda G.

Int J Cancer. 2005 Nov 20;117(4):587-95.

15.

Tumor-derived TGF-beta reduces the efficacy of dendritic cell/tumor fusion vaccine.

Kao JY, Gong Y, Chen CM, Zheng QD, Chen JJ.

J Immunol. 2003 Apr 1;170(7):3806-11.

16.

Simultaneous activation of T helper function can augment the potency of dendritic cell-based cancer immunotherapy.

Teramoto K, Ohshio Y, Fujita T, Hanaoka J, Kontani K.

J Cancer Res Clin Oncol. 2013 May;139(5):861-70. doi: 10.1007/s00432-013-1394-4. Epub 2013 Feb 15.

PMID:
23411688
17.

Deficiency in TLR2 but not in TLR4 impairs dendritic cells derived IL-10 responses to schistosome antigens.

Gao Y, Zhang M, Chen L, Hou M, Ji M, Wu G.

Cell Immunol. 2012;272(2):242-50. doi: 10.1016/j.cellimm.2011.10.007. Epub 2011 Oct 15.

PMID:
22063738
18.

The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.

Ojima T, Iwahashi M, Nakamura M, Matsuda K, Naka T, Nakamori M, Ueda K, Ishida K, Yamaue H.

Int J Oncol. 2006 Apr;28(4):947-53.

PMID:
16525645
20.

Induction of cross-priming of naive CD8+ T lymphocytes by recombinant bacillus Calmette-Guerin that secretes heat shock protein 70-major membrane protein-II fusion protein.

Mukai T, Maeda Y, Tamura T, Matsuoka M, Tsukamoto Y, Makino M.

J Immunol. 2009 Nov 15;183(10):6561-8. doi: 10.4049/jimmunol.0803857. Epub 2009 Oct 21.

Supplemental Content

Support Center